Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063621 | 1.00 | KDM4E (0.45) | KDM4ETSHRPOLBPKMHRH2 | |
| SCHEMBL1006226 | 1.00 | KDM4E (0.45) | KDM4ETSHRPOLBPKMHRH2 | |
| SCHEMBL1006794 | 0.88 | KDM4E (0.42) | KDM4ETSHRPOLBPKMAPEX1 | |
| SCHEMBL1007467 | 0.88 | KDM4E (0.42) | KDM4ETSHRPOLBPKMAPEX1 | |
| SCHEMBL1008007 | 0.88 | KDM4E (0.42) | KDM4ETSHRPOLBPKMAPEX1 | |
| SCHEMBL1007625 | 0.87 | KDM4E (0.54) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL7373455 | 0.86 | TSHR (0.44) | KDM4ETSHRPOLBPKML3MBTL1 | |
| SCHEMBL1008772 | 0.83 | KDM4E (0.45) | KDM4ETSHRPOLBPKMSMN1; SMN2 | |
| SCHEMBL2362299 | 0.83 | HSD17B10 (0.41) | HRH2HRH1SMN1; SMN2LTA4HGNAI3 | |
| SCHEMBL1008579 | 0.83 | KDM4E (0.45) | KDM4ETSHRPOLBPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071195-B2 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L | 2006-03-09 | — | — | US | disclosed |
| EP-1493742-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1202986-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2001009120-A1 | AMINE AND AMIDE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052388-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | KDM4E 834/4885TSHR 104/4885POLB 4531/4885 |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | KDM4E 854/4885TSHR 102/4885POLB 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.